Noven Provides Update on Vivelle-Dot(TM) Estrogen Patch

Total prescriptions for Vivelle-Dot(TM) in 2005 increased 11% compared to 2004. During the same period, the estrogen segment of the U.S. hormone therapy (HT) market decreased 9%. At the end of 2005, Vivelle-Dot(TM) held a 44.6% share of the transdermal estrogen therapy market, up from 40.2% at the end of 2004, and was the most dispensed transdermal estrogen product in the U.S. for the third consecutive year.

Aggregate total prescriptions for the three HT products offered by Novogyne (Vivelle-Dot(TM), original Vivelle(R) and CombiPatch(R))increased 4% in 2005 compared to 2004, while the overall U.S. HTmarket declined 9% for the same period.

Noven also announced that, based on a review of preliminaryfinancial results for 2005, Novogyne's 2005 annual net sales ofVivelle-Dot(TM) are expected to exceed $100 million for the firsttime.

Noven confirmed that, effective January 1, 2006, the Novogynesales force, formerly a third-party contract sales force, becamedirect employees of Noven, with Novogyne continuing to bear theassociated expenses. "The conversion of the sales force from contractto employee status reflects our commitment to the hormone therapycategory, and our confidence in a sales team that has takenVivelle-Dot(TM) to market leadership," said Robert C. Strauss,President, CEO & Chairman of Noven, and President of Novogyne. Withthe addition of the Novogyne sales force, Noven currently hasapproximately 500 employees.

Prescription and market share information appearing in thisrelease is based on third party data for the relevant products andperiods.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are sold in over 30 countries, and a range of new products are being developed in collaboration with Shire plc, Novartis Pharma AG, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. See http://www.noven.com for additional information.

Except for historical information contained herein, the mattersdiscussed in this press release contain forward-looking statementswithin the meaning of Section 27A of the Securities Act of 1933 andSection 21E of the Securities Exchange Act of 1934 that involvesubstantial risks and uncertainties. Actual results, performance orachievements could differ materially from those contemplated,expressed or implied by the forward-looking statements containedherein. These forward-looking statements are based largely on thecurrent expectations of Noven and are subject to a number of risks anduncertainties that are subject to change based on factors which are,in many instances, beyond Noven's control. These risks anduncertainties include: risks associated with the use of preliminaryfinancial information, including the possibility that final net salesinformation for Vivelle-Dot(TM) could differ from the preliminaryinformation noted in this press release; risks related to Noven'sdependence on Novartis to perform all of Novogyne's financial,accounting, inventory, distribution, revenues and sales deductionsfunctions; risks and uncertainties relating to the integration ofNovogyne's contract sales force into Noven's employee force, includingthe risk that such integration may be unsuccessful or prove morecostly than expected; and the risk that the past performance ofVivelle-Dot(TM), Novogyne or Noven may not be indicative of futureperformance due to a number of risks and uncertainties, includingthose set forth in Noven's Form 10-K for the year ended December 31,2004 as well as other reports filed from time to time with theSecurities and Exchange Commission.